Epstein-Barr virus - molecular basis for malignant transformation

Abstract

Epstein-Barr (EBV) is a widespread virus which can be detected in more than 90% of world population. Primary EBV infection during adolescence and adultness results in infectious mononucleosis, while in children it is usually asymptomatic. EBV is responsible for different malignant forms of B-cell or epithelial cancers, such as Hodgkin's and non-Hodgkin’s lymphoma, Burkitt's lymphoma, post-transplant lymphoproliferative disorders, nasopharyngeal carcinoma, hairy leukoplakia and HIV-associated lymphomas. Evidence exists that infection with EBV is also linked with a higher risk of hepatocellular and gastric cancers, as well as autoimmune diseases. EВV shows two alternative life cycles – latent and lytic. After the primary infection, the virus remains in B lymphocytes in latency, while the lytic infection takes place predominantly in the epithelial cells and can last for months with constant virus release in saliva and nasopharyngeal secretion. Unlike other herpes viruses, development of oncological diseases is linked with the latent cycle, as a result of immune response‘s failure to control latently infected cells. With the present work we try to concisely review the current knowledge about mechanisms of EBV pathogenesis in humans and to summarize recent findings in the field.